127.67 USD
+6.6 (+5.45%)
129 USD
+1.33 (+1.04%)
We assign a fundamental rating of 6 out of 10 to TMDX. TMDX was compared to 184 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of TMDX get a neutral evaluation. Nothing too spectacular is happening here. TMDX is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings would make TMDX suitable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year TMDX was profitable.
In the past year TMDX had a positive cash flow from operations.
In the past 5 years TMDX reported 4 times negative net income.
In the past 5 years TMDX reported 4 times negative operating cash flow.
1.2 Ratios
TMDX's Return On Assets of 9.70% is amongst the best of the industry. TMDX outperforms 93.48% of its industry peers.
With an excellent Return On Equity value of 25.84%, TMDX belongs to the best of the industry, outperforming 96.74% of the companies in the same industry.
TMDX has a Return On Invested Capital of 8.75%. This is amongst the best in the industry. TMDX outperforms 88.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.7% | ||
| ROE | 25.84% | ||
| ROIC | 8.75% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TMDX has a Profit Margin of 16.20%. This is amongst the best in the industry. TMDX outperforms 92.93% of its industry peers.
TMDX has a Operating Margin of 16.94%. This is amongst the best in the industry. TMDX outperforms 87.50% of its industry peers.
TMDX's Gross Margin of 60.28% is fine compared to the rest of the industry. TMDX outperforms 60.33% of its industry peers.
TMDX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.94% | ||
| PM (TTM) | 16.2% | ||
| GM | 60.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
2. Health
2.1 Basic Checks
TMDX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for TMDX has been increased compared to 1 year ago.
The number of shares outstanding for TMDX has been increased compared to 5 years ago.
Compared to 1 year ago, TMDX has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.47 indicates that TMDX is not in any danger for bankruptcy at the moment.
TMDX's Altman-Z score of 5.47 is fine compared to the rest of the industry. TMDX outperforms 78.80% of its industry peers.
TMDX has a debt to FCF ratio of 4.24. This is a neutral value as TMDX would need 4.24 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.24, TMDX is in the better half of the industry, outperforming 79.89% of the companies in the same industry.
TMDX has a Debt/Equity ratio of 1.43. This is a high value indicating a heavy dependency on external financing.
TMDX has a Debt to Equity ratio of 1.43. This is in the lower half of the industry: TMDX underperforms 79.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.24 | ||
| Altman-Z | 5.47 |
ROIC/WACC1.08
WACC8.07%
2.3 Liquidity
TMDX has a Current Ratio of 7.69. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
TMDX has a better Current ratio (7.69) than 88.59% of its industry peers.
TMDX has a Quick Ratio of 7.13. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 7.13, TMDX belongs to the top of the industry, outperforming 89.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.69 | ||
| Quick Ratio | 7.13 |
3. Growth
3.1 Past
TMDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 162.77%, which is quite impressive.
Looking at the last year, TMDX shows a very strong growth in Revenue. The Revenue has grown by 41.20%.
TMDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 79.64% yearly.
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
3.2 Future
TMDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.52% yearly.
The Revenue is expected to grow by 21.23% on average over the next years. This is a very strong growth
EPS Next Y163.67%
EPS Next 2Y70.37%
EPS Next 3Y53.74%
EPS Next 5Y44.52%
Revenue Next Year39.71%
Revenue Next 2Y29.71%
Revenue Next 3Y25.57%
Revenue Next 5Y21.23%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 51.69, TMDX can be considered very expensive at the moment.
TMDX's Price/Earnings ratio is a bit cheaper when compared to the industry. TMDX is cheaper than 68.48% of the companies in the same industry.
When comparing the Price/Earnings ratio of TMDX to the average of the S&P500 Index (26.39), we can say TMDX is valued expensively.
TMDX is valuated quite expensively with a Price/Forward Earnings ratio of 43.55.
Based on the Price/Forward Earnings ratio, TMDX is valued a bit cheaper than the industry average as 70.11% of the companies are valued more expensively.
TMDX is valuated expensively when we compare the Price/Forward Earnings ratio to 23.84, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 51.69 | ||
| Fwd PE | 43.55 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, TMDX is valued a bit cheaper than the industry average as 69.57% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, TMDX is valued a bit cheaper than the industry average as 77.17% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 36.18 | ||
| EV/EBITDA | 36.23 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TMDX's earnings are expected to grow with 53.74% in the coming years.
PEG (NY)0.32
PEG (5Y)N/A
EPS Next 2Y70.37%
EPS Next 3Y53.74%
5. Dividend
5.1 Amount
TMDX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
127.67
+6.6 (+5.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners111.26%
Inst Owner Change1.46%
Ins Owners2.95%
Ins Owner Change-0.16%
Market Cap4.36B
Revenue(TTM)566.35M
Net Income(TTM)91.77M
Analysts83
Price Target147.31 (15.38%)
Short Float %23.26%
Short Ratio8.23
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.22%
Min EPS beat(2)84.39%
Max EPS beat(2)100.04%
EPS beat(4)4
Avg EPS beat(4)92.06%
Min EPS beat(4)16.42%
Max EPS beat(4)167.38%
EPS beat(8)7
Avg EPS beat(8)202.42%
EPS beat(12)10
Avg EPS beat(12)118.6%
EPS beat(16)12
Avg EPS beat(16)90.24%
Revenue beat(2)1
Avg Revenue beat(2)0.71%
Min Revenue beat(2)-2.93%
Max Revenue beat(2)4.34%
Revenue beat(4)3
Avg Revenue beat(4)5.83%
Min Revenue beat(4)-2.93%
Max Revenue beat(4)13.8%
Revenue beat(8)6
Avg Revenue beat(8)7.35%
Revenue beat(12)10
Avg Revenue beat(12)12.14%
Revenue beat(16)14
Avg Revenue beat(16)18.13%
PT rev (1m)-1.35%
PT rev (3m)-1.42%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.51%
EPS NY rev (1m)0.62%
EPS NY rev (3m)10.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 51.69 | ||
| Fwd PE | 43.55 | ||
| P/S | 7.7 | ||
| P/FCF | 36.18 | ||
| P/OCF | 24.46 | ||
| P/B | 12.28 | ||
| P/tB | 12.77 | ||
| EV/EBITDA | 36.23 |
EPS(TTM)2.47
EY1.93%
EPS(NY)2.93
Fwd EY2.3%
FCF(TTM)3.53
FCFY2.76%
OCF(TTM)5.22
OCFY4.09%
SpS16.57
BVpS10.4
TBVpS10
PEG (NY)0.32
PEG (5Y)N/A
Graham Number24.04
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.7% | ||
| ROE | 25.84% | ||
| ROCE | 11.08% | ||
| ROIC | 8.75% | ||
| ROICexc | 18.94% | ||
| ROICexgc | 19.61% | ||
| OM | 16.94% | ||
| PM (TTM) | 16.2% | ||
| GM | 60.28% | ||
| FCFM | 21.29% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
F-Score7
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.24 | ||
| Debt/EBITDA | 4.16 | ||
| Cap/Depr | 224.51% | ||
| Cap/Sales | 10.19% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 146.57% | ||
| Profit Quality | 131.41% | ||
| Current Ratio | 7.69 | ||
| Quick Ratio | 7.13 | ||
| Altman-Z | 5.47 |
F-Score7
WACC8.07%
ROIC/WACC1.08
Cap/Depr(3y)951.97%
Cap/Depr(5y)615.69%
Cap/Sales(3y)34.99%
Cap/Sales(5y)23.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
EPS Next Y163.67%
EPS Next 2Y70.37%
EPS Next 3Y53.74%
EPS Next 5Y44.52%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
Revenue Next Year39.71%
Revenue Next 2Y29.71%
Revenue Next 3Y25.57%
Revenue Next 5Y21.23%
EBIT growth 1Y205.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year317.92%
EBIT Next 3Y87.46%
EBIT Next 5Y68.49%
FCF growth 1Y187.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y802.91%
OCF growth 3YN/A
OCF growth 5YN/A
TRANSMEDICS GROUP INC / TMDX FAQ
Can you provide the ChartMill fundamental rating for TRANSMEDICS GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to TMDX.
What is the valuation status for TMDX stock?
ChartMill assigns a valuation rating of 5 / 10 to TRANSMEDICS GROUP INC (TMDX). This can be considered as Fairly Valued.
How profitable is TRANSMEDICS GROUP INC (TMDX) stock?
TRANSMEDICS GROUP INC (TMDX) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for TMDX stock?
The Price/Earnings (PE) ratio for TRANSMEDICS GROUP INC (TMDX) is 51.69 and the Price/Book (PB) ratio is 12.28.
What is the financial health of TRANSMEDICS GROUP INC (TMDX) stock?
The financial health rating of TRANSMEDICS GROUP INC (TMDX) is 6 / 10.